Technology Transfer

Industrial partnerships and technology development

Coordinated by the Technology Development Office (TDO) of Imagine and executed in close cooperation with the technology transfer offices of our institutional partners (Inserm, APHP and Paris Descartes University), technology development includes :

  • sourcing programs, results and technologies of interest to industry,
  • protecting inventions e.g. through patent applications,
  • performing proof-of-concept developments,
  • approaching potential partners, ranging from start-up to large pharmaceutical companies, with the aim of setting up collaboration or license agreements.

These activities, enabled by our efficient intellectual property, regulatory and partnering policies, underpin win/win relationships with industrial partners.

Our interest in partnering with industry

At Imagine, we consider that industrial partners are essential components of the therapeutic and diagnostic innovation process we are involved in. Indeed, they can provide expertise and resources that will successfully complement our research and clinical activities. Furthermore, they have the ability to exploit our work by developing novel treatments or diagnostic tools for the benefit of patients. Out-licensing is obviously a frequently adopted approach, along with pre-competitive, collaborative work where risks and benefits are shared. This is especially suitable for early-stage, highly innovative projects.


Why partnering with Imagine Institute?

Innovative and patient-centred research programs. Our activities mainly focus on genetic and rare diseases in a wide range of therapeutic areas. In most cases, our research programs are initially catalysed by the observation of patients. The ultimate goal is to develop new treatments and/or diagnostic tools by investigating medically-relevant targets and biomarkers (genes, gene products or pathways), developing disease models and testing the most appropriate therapeutic approaches from preclinical studies through to clinical trials in various contexts. In addition to addressing unmet medical needs in the field of rare diseases, our research can also lead to new ways of considering more frequent conditions. Indeed, rare diseases sometimes share the same genes, pathways or therapeutic targets as more prevalent diseases.


Translational research. Imagine Institute provides unique assets to foster translational research and accelerate the development of new diagnostic and therapeutic solutions for patients :

  • scientists and physicians working together in a ultra-modern 19,000 sqm building located on the Necker Children’s Hospital campus,
  • cutting-edge technical facilities (e.g. genomics/next-generation sequencing, bioinformatics, imaging and preclinical models),
  • clinical facilities that can provide methodological advice as well as access to large, rationalized cohorts of accurately phenotyped and genotyped patients,

Advantageously, business development and administrative teams are closely interfaced with the R&D staff; the focus is on shortening timelines and reducing complexity in bench-to-bedside projects, in collaboration with other Imagine teams and/or academic or industrial partners. Efficient processes and policies have been established for handling intellectual property and enabling win/win partnerships.

We believe our activities can be achieved in collaboration with pharmaceutical and biotech companies, whose expertise and resources will necessarily shorten the time lines for the delivery of solutions meeting the patients and their families’ needs. Thus, Imagine is striving to become a key player and collaborative partner throughout the value chain in patient-centred therapeutic and diagnostic innovation.

Partnering opportunities include :

  • Drug discovery or repurposing projects : testing/screening drug candidates against medically relevant targets studied at Imagine and access to unique preclinical resources (in vitro and in vivo).
  • Clinical proof-of-concept and drug development projects : access to cohorts of accurately phenotyped and genotyped patients for the performance of clinical trials.
  • Innovative therapeutic approaches : gene therapy, exon skipping, cell therapy, transplantation, novel enzyme replacement therapy and drug therapy, etc
  • Innovative diagnostic approaches : prenatal and pre-implantation diagnoses, prenuptial screening, susceptibility/prognostic/follow-up biomarkers, etc.

Main figures

  • 30 active patent families
  • Dozens of license or collaboration agreements
  • 2 companies founded